391870 Design and Evaluation of a Potential Universal Influenza A Vaccine Based on M2e-Conjugated Gold Nanoparticles

Wednesday, November 19, 2014: 2:00 PM
201 (Hilton Atlanta)
Wenqian Tao and Harvinder S. Gill, Chemical Engineering, Texas Tech University, Lubbock, TX

Influenza virus causes serious respiratory illness. Due to the high mutation rate in influenza genes antigenic drift creates a new strain each year. Consequently there is significant economic burden to monitor virus activity and to create and distribute new influenza vaccines to the public each year. Furthermore, emergence of a novel influenza subtype which is virulent and has never circulated amongst humans could cause a devastating pandemic. It is therefore critical that more universal vaccination strategies be developed against influenza A that can protect against all influenza A subtypes. The 23 amino acid-long extracellular domain of the viral transmembrane protein M2 (M2e) has remained highly conserved since the 1918 pandemic, and is considered a good candidate for the development of a universal influenza vaccine. However, M2e is poorly immunogenic. Our studies show that by attaching consensus M2e peptide to gold nanoparticles (Au) and using CpG as a soluble adjuvant (AuNP-M2e+sCpG vaccine) a broad heterosubtypic protection can be observed against A/PR/8/34 (H1N1), A/California/04/2009 (H1N1) pandemic strain, A/Victoria/3/75 (H3N2),  and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1). Furthermore, long term protection at 8 months post vaccination was observed. Overall, this study suggests that AuNP-M2e+sCpG vaccine holds potential as a universal influenza vaccine.

Extended Abstract: File Not Uploaded
See more of this Session: Applications in Immunology and Immunotherapy
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division